Press Release
MICHAEL SECKLER APPOINTED NATIONAL SALES DIRECTOR FOR FERRING PHARMACEUTICALS
Contact: |
Kelly Laban |
Pictured: Michael D. Seckler, appointed national sales director for Ferring Pharmaceuticals
Suffern, NY – January 11, 2005 – Ferring Pharmaceuticals announced today the appointment of Michael Seckler, of Warren, NJ, to national sales director. Seckler joined the Company in February 2003 as district manager, eastern states. In his new role, he will be responsible for successful implementation of the sales strategy for Ferring’s product line.
“Seckler excelled as a district manager, leading his district to an unprecedented performance level in the East,” said Olivier Delannoy, vice president, sales, Ferring Pharmaceuticals. “We are confident that his dedication and strong leadership ability will ensure success in his new position.”
Prior to joining Ferring, Seckler was a specialty district manager for Pharmacia. He previously held the director of sales position at Caresoft and spent 10 years at Schering Plough, where he held a variety of positions, including district manager; product manager; and manager, managed care sales training.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned,
international pharmaceutical company, markets Bravelle® (urofollitropin for
injection, purified), Repronex® (menotropins for injections, USP) and Novarel™ (chorionic
gonadotropin for injection, USP) in the U.S. to infertility specialists and
their patients.
Ferring also offers the Q∙Cap™, the first needle-free reconstitution device, for use with its line of fertility treatments. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.
# # #